Background & Aim
Cardiac amyloidosis is an infiltrative cardiomyopathy associated with significant morbidity and mortality. Frailty, a biologic syndrome of decreased physiologic reserve, may be common and clinically significant in this population, yet remains insufficiently characterised. We aim to determine the prevalence and characteristics of frailty among adults with cardiac amyloidosis, and examine its association with functional status, quality of life, and disease severity.
Methods & Design
As a prospective, observational, single-centre cohort study, adults with confirmed cardiac amyloidosis will undergo standardised frailty assessment. The prevalence of physical frailty (≥3 criteria) and cognitive frailty (≥2 frailty criteria plus mild cognitive impairment (MoCA <26)) will be evaluated, and the distribution of individual criteria summarised. Disease characterisation will include functional status, quality of life, disease staging, and biomarkers at baseline and 12-month follow-up. Associations between frailty and clinical variables will be explored using descriptive and univariate analyses.